V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210003872 | 210007127 | 1.66 | 72.75 | Adjuvant (A) | null | 2018-04-17 | null | null | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + PACLITAXEL | 100048535 |
| 210003874 | 210007129 | null | 127 | null | null | 2016-09-02 | Cyclophosphamide + Docetaxel | 02 | null | LETROZOLE + PALBOCICLIB | 101181685 |
| 210003876 | 210007130 | 1.47 | 90.3 | Palliative (P) | null | 2018-02-20 | null | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100468627 |
| 210000002 | 210007136 | 1.55 | null | Palliative (P) | 2019-07-28 | 2019-08-14 | FEC | null | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101666120 |
| 210000022 | 210007137 | 1.58 | 87.5 | Neo-adjuvant (N) | 2020-09-30 | 2021-12-07 | Letrozole + Palbociclib | 02 | N | ATEZOLIZUMAB + NAB-PACLITAXEL | 100160192 |
| 210000050 | 210007139 | 1.72 | 63 | Adjuvant (A) | 2019-08-11 | 2019-09-26 | null | null | N | TRIAL UNSPECIFIED | 100148879 |
| 210000169 | 210007142 | null | null | null | 2019-09-13 | 2019-09-19 | FEC 100 | null | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101740701 |
| 210000232 | 210007144 | 1.68 | 66.8 | null | 2021-03-22 | 2021-03-22 | ATEZOLIZUMAB + NAB PACLITAXEL | 02 | null | EPIRUBICIN | 101408906 |
| 210000413 | 210007149 | 1.65 | 63.7 | Neo-adjuvant (N) | null | 2017-05-16 | FEC + DOCETAXEL | null | N | FEC + DOCETAXEL | 101261105 |
| 210000562 | 210007151 | 1.68 | 61.45 | Palliative (P) | 2019-12-09 | 2019-12-24 | TRASTUZUMAB EMTANSINE | N | N | CARBOPLATIN | 101698914 |
| 210000814 | 210007153 | 1.57 | 63 | Palliative (P) | 2018-10-22 | 2018-11-08 | null | null | N | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 101665920 |
| 210000892 | 210007157 | 1.56 | 71.5 | Palliative (P) | null | 2014-08-06 | null | 02 | N | CAPECITABINE | 100248794 |
| 210000921 | 210007160 | 1.67 | 70.2 | Adjuvant (A) | null | 2017-06-09 | EC | null | N | EC | 101314024 |
| 210000923 | 210007161 | 1.54 | 58.2 | Palliative (P) | 2017-02-02 | 2017-02-18 | FEC 100 | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100847005 |
| 210000986 | 210007162 | 1.62 | 68.08 | null | 2019-08-02 | 2019-08-23 | null | N | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101865716 |
| 210001023 | 210007163 | 1.59 | 75.4 | null | 2018-09-02 | 2018-09-17 | FEC | null | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101525834 |
| 210001086 | 210007166 | null | null | null | 2019-04-26 | 2019-05-07 | Epirubicin (weekly) | null | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101663547 |
| 210001109 | 210007167 | 1.71 | 83.3 | Adjuvant (A) | 2017-11-17 | 2017-12-03 | FEC + DOCETAXEL | null | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 100904517 |
| 210001126 | 210007170 | 1.62 | 58.3 | Adjuvant (A) | 2017-09-05 | 2018-12-31 | null | null | N | VINORELBINE | 101674658 |
| 210001177 | 210007171 | null | null | null | 2019-09-20 | 2019-10-05 | EC + DOCETAXEL | null | null | CARBOPLATIN + PACLITAXEL | 101683789 |
| 210001199 | 210007173 | 1.58 | null | Palliative (P) | null | 2020-07-22 | FEC 60 or 75 | null | N | FEC | 100188873 |
| 210001255 | 210007176 | null | null | null | 2019-10-05 | 2019-10-07 | FEC + DOCETAXEL | N | null | FEC + DOCETAXEL | 100481126 |
| 210001286 | 210007177 | 1.57 | null | Neo-adjuvant (N) | 2020-01-04 | 2020-01-17 | TRASTUZUMAB EMTANSINE | 02 | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100797849 |
| 210001373 | 210007178 | 1.58 | 71.35 | Palliative (P) | 2019-03-25 | 2019-04-08 | FEC + DOCETAXEL | N | null | FEC + DOCETAXEL | 101373807 |
| 210001402 | 210007179 | 1.52 | 76.2 | null | 2017-01-07 | 2017-01-16 | ATEZOLIZUMAB + NAB PACLITAXEL | null | null | CAPECITABINE | 101758627 |
| 210001446 | 210007181 | null | null | Neo-adjuvant (N) | null | 2016-03-26 | FEC | N | N | FEC | 101389583 |
| 210001528 | 210007183 | null | 66.3 | null | null | 2022-05-14 | Vinorelbine (oral) | 02 | null | VINORELBINE | 101250492 |
| 210001592 | 210007186 | 0 | 65.2 | Adjuvant (A) | 2016-10-22 | 2016-11-06 | Epirubicin | null | N | ROSCO TRIAL | 101801550 |
| 210001624 | 210007188 | 1.64 | 104.5 | Palliative (P) | 2019-10-01 | 2019-10-19 | FEC + DOCETAXEL | N | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 101284527 |
| 210001640 | 210007190 | 1.85 | 0 | null | 2019-04-12 | 2019-04-13 | EC | null | null | EC | 101143276 |
| 210001782 | 210007193 | null | null | null | 2019-12-28 | 2019-12-31 | Paclitaxel+Trastuzumab wkly Maint | null | null | PACLITAXEL + TRASTUZUMAB | 100854706 |
| 210001795 | 210007194 | 1.48 | 78.4 | null | 2016-02-22 | 2016-03-09 | Everolimus 10mg | null | null | PERTUZUMAB + TRASTUZUMAB | 100924654 |
| 210001844 | 210007197 | null | null | null | 2019-02-09 | 2019-04-23 | Paclitaxel+Trastuzumab wkly Maint | 02 | null | PACLITAXEL + TRASTUZUMAB | 100737108 |
| 210001876 | 210007198 | null | null | null | 2018-09-28 | 2018-10-13 | FEC 60 or 75 | 02 | null | FEC | 100936518 |
| 210001944 | 210007200 | 1.7 | 123 | Neo-adjuvant (N) | null | 2016-09-03 | FEC 60 or 75 | null | N | FEC | 101002234 |
| 210001963 | 210007203 | 1.63 | 117.8 | Neo-adjuvant (N) | 2019-12-30 | 2020-01-10 | EC | 02 | N | EC | 101232145 |
| 210001972 | 210007204 | null | null | null | null | 2020-10-06 | Capecitabine | N | null | CAPECITABINE | 101672086 |
| 210002016 | 210007206 | 1.7 | 65.3 | null | 2014-05-26 | 2014-08-21 | CMF | 02 | null | EPIRUBICIN | 101019512 |
| 210002038 | 210007207 | 1.56 | 59.7 | Adjuvant (A) | null | 2018-11-17 | FEC 100 | null | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101316970 |
| 210002052 | 210007208 | 1.63 | 58.1 | null | null | 2019-12-26 | FEC 100 | null | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100843902 |
| 210002091 | 210007209 | null | null | Palliative (P) | null | 2019-08-18 | FEC + DOCETAXEL | N | N | FEC + DOCETAXEL | 101005329 |
| 210002107 | 210007210 | 1.74 | 60.7 | Adjuvant (A) | 2017-04-28 | 2017-09-29 | null | N | N | TRIAL UNSPECIFIED | 101536240 |
| 210002112 | 210007211 | 1.56 | 90.7 | null | null | 2016-07-01 | null | null | null | ATEZOLIZUMAB + NAB-PACLITAXEL | 100717205 |
| 210002144 | 210007213 | 1.6 | 92 | Adjuvant (A) | null | 2019-01-24 | null | 02 | N | VINORELBINE | 100163344 |
| 210002229 | 210007216 | 1.53 | 66.7 | Neo-adjuvant (N) | 2019-06-24 | 2019-09-24 | FEC 60 OR 75 + DOCETAXEL | 02 | N | FEC + DOCETAXEL | 101584469 |
| 210002260 | 210007217 | null | null | Neo-adjuvant (N) | 2019-12-18 | 2019-12-18 | FEC 100 | N | N | FEC | 101555067 |
| 210002362 | 210007220 | 1.61 | 60.25 | Adjuvant (A) | null | 2019-03-06 | TCH (21 day Trastuzumab) Maint | 02 | N | CAPECITABINE | 100908757 |
| 210002373 | 210007221 | 1.54 | 90.8 | null | 2020-07-18 | 2020-07-28 | null | 02 | null | ATEZOLIZUMAB + NAB-PACLITAXEL | 101830721 |
| 210002431 | 210007223 | 1.6 | 58.5 | Adjuvant (A) | 2019-11-03 | 2019-12-02 | FEC 100 | null | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100024558 |
| 210002467 | 210007226 | null | null | null | null | 2019-11-11 | FEC + DOCETAXEL | N | null | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 100194392 |